GlassScriptPhysician profile
Stephanie Spector
NPI 1316458086
$6,421.88
in general payments reported to CMS, 2019-2025
34 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,530 · 2022: $1,642 · 2023: $866 · 2024: $555 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,249.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $866.23 | 2021-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Rhythmia Mapping System |
| Abbott Laboratories | $849.87 | 2021-2025 | Merlin@Home, Jot Dx, Aveir |
| Biotronik INC. | $744.54 | 2021-2025 | Biomonitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $667.76 | 2021-2025 | Lifevest |
| Cvrx, INC. | $476.63 | 2022-2025 | Barostim Neo System |
| Medtronic, INC. | $471.92 | 2021-2025 | Pulseselect, Cobalt Dr Mri Surescan, Affera Mapping System |
| Merz North America, INC. | $407.01 | 2023-2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $314.02 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $193.57 | 2022-2024 | Assure Wcd |
| Biosense Webster, INC. | $158.31 | 2022-2023 | Carto 3 |
| Edwards Lifesciences Corporation | $142.14 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2025 | Camzyos |
| Galderma Laboratories, L.P. | $120.53 | 2023 | |
| Sanofi-Aventis U.S. LLC | $102.78 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $85.69 | 2025 | Keytruda, Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $84.56 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.37 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $56.13 | 2025 | |
| Elutia, INC. | $50.50 | 2024 | Ecm Patch,Pouch |
| Geron Corporation | $48.97 | 2025 | Rytelo |
| Novo Nordisk INC | $48.84 | 2025 | Wegovy |
| Janssen Biotech, INC. | $48.09 | 2025 | Rybrevant, Darzalex, Talvey |
| Kiniksa Pharmaceuticals, LTD. | $42.22 | 2021-2023 | Arcalyst |
| Pfizer INC. | $33.81 | 2023-2025 | |
| Tersera Therapeutics LLC | $31.78 | 2025 | Quzyttir |
| Alnylam Pharmaceuticals INC. | $29.78 | 2025 | Onpattro |
| Incyte Corporation | $27.11 | 2025 | Zynyz |
| Bridgebio Pharma, INC. | $27.06 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.78 | 2025 | Jardiance |
| Puma Biotechnology, INC. | $20.35 | 2025 | |
| Esperion Therapeutics, INC. | $19.12 | 2025 | Nexletol |
| Amgen INC. | $19.06 | 2025 | Repatha |
| Convatec INC. | $17.60 | 2024 | |
| Altathera Pharmaceuticals LLC | $16.91 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.